Curis (NASDAQ:CRIS) Announces Earnings Results

Curis (NASDAQ:CRIS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.07), Zacks reports. The business had revenue of $1.14 million for the quarter, compared to analysts’ expectations of $3.25 million.

Here are the key takeaways from Curis’ conference call:

• Take Aim Lymphoma (PCNSL) registrational study is enrolling on track and, after FDA/EMA discussions, is expected to support accelerated submissions, with full enrollment targeted in ~12–18 months and a potential filing timeline into 2027.
• Curis has initiated a proof-of-concept CLL trial adding emavusertib to BTKI to deepen responses and enable time-limited therapy; U.S. and EU sites are activating and the company expects initial data at ASH (Dec 2026).
• Early data from the AML triplet study (emavusertib + azacitidine + venetoclax) showed promising activity, with 5 of 8 evaluable patients converting from MRD positive to undetectable disease, though the cohort size is small.
• Q4 2025 net income of $19.4M was driven by a $27.2M one-time non-cash gain from the sale of Erivedge, and management expects no meaningful revenue going forward after that sale.
• Company reports cash and equivalents plus January 2026 proceeds should fund operations into the second half of 2027, with up to an additional $20.2M contingent on exercise of warrants triggered by dosing the fifth CLL patient.

Curis Stock Performance

Shares of NASDAQ CRIS opened at $0.76 on Friday. Curis has a 52-week low of $0.75 and a 52-week high of $3.13. The business has a fifty day moving average of $0.98 and a two-hundred day moving average of $1.26. The stock has a market cap of $10.39 million, a PE ratio of -0.21 and a beta of 3.02.

Hedge Funds Weigh In On Curis

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its position in Curis by 8.7% in the third quarter. Armistice Capital LLC now owns 978,190 shares of the biotechnology company’s stock valued at $1,624,000 after buying an additional 78,265 shares in the last quarter. Maverick Capital Ltd. raised its stake in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after acquiring an additional 49,554 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Curis by 37.3% in the 4th quarter. Renaissance Technologies LLC now owns 240,917 shares of the biotechnology company’s stock worth $238,000 after acquiring an additional 65,404 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in Curis by 2,883,237.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 230,667 shares of the biotechnology company’s stock worth $228,000 after acquiring an additional 230,659 shares during the last quarter. Finally, Squarepoint Ops LLC increased its holdings in Curis by 46.2% during the 4th quarter. Squarepoint Ops LLC now owns 86,483 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 27,343 shares in the last quarter. 29.97% of the stock is owned by institutional investors.

Analyst Ratings Changes

CRIS has been the subject of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $17.00 price objective on shares of Curis in a report on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of Curis in a research report on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $17.00.

About Curis

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.